[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633056":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":44,"collaborators":46,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":99,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Barcelonabeta Brain Research Center, Pasqual Maragall Foundation","OTHER",[8,12,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":10},"European",null,"50 participants from any European country",{"label":13,"type":10,"description":14,"interventionNames":10},"South Asian","50 participants from Pakistan, India, Bangladesh",{"label":16,"type":10,"description":17,"interventionNames":10},"Filipinos","50 participants from Philippines",{"label":19,"type":10,"description":20,"interventionNames":10},"Latin America","50 participants from any country of South America",{"label":22,"type":10,"description":23,"interventionNames":10},"Maghrebi","50 participants from any country of the Magheb region (Morocco, Tunisia, Mauritania, Algeria, Libya)",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Gianmarco Iaccarino","CONTACT","+34‭ 933263190","giaccarino@barcelonabeta.org",[31],{"facility":32,"status":10,"city":33,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"BarcelonaBeta Brain Research Center - EAP Raval Sud","Barcelona","Spain","ES",{"type":37,"coordinates":38},"Point",[39,40],2.15899,41.38879,{"lat":40,"lon":39},[43],{"name":26,"role":27,"phone":10,"phoneExt":10,"email":29},{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[47,49,51,53],{"name":48,"class":6},"Universitat Pompeu Fabra",{"name":50,"class":6},"Hospital del Mar Research Institute (IMIM)",{"name":52,"class":6},"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina",{"name":54,"class":6},"Hospital del Mar","100633056","div-ad-barcelona-alzheimers-blood-based-biomakers-for-a-diverse-community-100633056",false,"NCT07521722","DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community","DIV-AD","INCLUSION CRITERIA\n\n* Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent\n* Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context.\n* Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling.\n* Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.\n\nEXCLUSION CRITERIA\n\n* Cognitive decline defined by CDR\\>0.\n* Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life\n* Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance\u002Finterpretation of the study procedures and\u002For with future permanence in the study.\n* Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc).\n* Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or hemorrhagic stroke, brain tumours and any other etiologies that can cause acquired brain damage (i.e., chemotherapy or brain radiotherapy).\n* Parkinson's disease, epilepsy under treatment and with frequent seizures (\\> 1\u002Fmonth) in the last year, multiple sclerosis or other neurodegenerative diseases.",true,"ALL","50 Years","75 Years",{"count":67,"type":68},250,"ESTIMATED","OBSERVATIONAL","The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona.\n\nIt will also examine how factors such as age, income, education, and health conditions may affect these levels.\n\nIn addition, the study will identify barriers that may make it difficult to use these blood tests in primary care.\n\nThe final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.",[72,73,74,75],"Alzheimer Disease","Cognitive Dysfunction, Cognitive Disorder","Dementia","Neurodegenerative Disease",[77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98],"Alzheimer's disease","AD","Blood-based biomarkers","Plasma biomarkers","Phosphorylated tau","Amyloid beta","Neurofilament light chain","GFAP","Ethnic diversity","Health disparities","Cognitively unimpaired","Preclinical Alzheimer's disease","Primary care","Dementia prevention","Cross-cultural cognitive assessment","RUDAS","Dementia knowledge","Dementia stigma","Genetic ancestry","Migrant populations","Health equity","Diversity","NOT_YET_RECRUITING","2026-04-07",{"date":102,"type":103},"2026-04-13","ACTUAL",{"date":105,"type":68},"2026-04-27",{"date":107,"type":68},"2029-01-01",{"name":5,"class":6},1]